FMP

FMP

Enter

ETTX - Entasis Therapeutics...

photo-url-https://images.financialmodelingprep.com/symbol/ETTX.png

Entasis Therapeutics Holdings Inc.

ETTX

NASDAQ

Inactive Equity

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

2.19 USD

-0.00999999 (-0.457%)

ETTX Financial Statements

Year

2021

2020

2019

2018

Total Revenue

0

0

7M

5M

Cost of Revenue

0

0

0

0

Gross Profit

0

0

7M

5M

Operating Expenses

52.32M

50.67M

51.64M

37.87M

Research and Development

37.1M

41.02M

40.17M

33.05M

Selling, General & Administrative Expenses

15.21M

13.21M

13.77M

10.16M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

15.21M

13.21M

13.77M

10.16M

Other Expenses

0

-3.56M

-2.3M

-5.34M

Operating Income

-47.14M

-54.23M

-46.94M

-38.21M

Total Other Income/Expenses Net

0

3.73M

3.76M

5.73M

Income Before Tax

-47.14M

-50.5M

-43.17M

-32.48M

Income Tax

0

3.73M

677k

472k

Net Income

-47.14M

-50.5M

-43.85M

-32.95M

Basic EPS

-1

-2.1

-3.33

-9.64

EPS Diluted

-1

-2.1

-3.33

-9.64

Basic Average Shares

47.31M

24.06M

13.16M

3.42M

Diluted Average Shares

47.31M

24.06M

13.16M

3.42M

EBITDA

-47.04M

-50.35M

-43.03M

-32.32M

Retained Earning Schedule

Year

2021

2020

2019

2018

Retained Earnings (Previous Year)

-184.46M

-133.96M

-90.11M

-57.17M

Net Income

-47.14M

-50.5M

-43.85M

-32.95M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-231.6M

-184.46M

-133.96M

-90.11M

Other Distributions

-47.14M

-50.5M

-43.85M

-32.94M

PPE Schedule

Year

2021

2020

2019

2018

Gross PPE

802k

1.36M

1.97M

419k

Annual Depreciation

104k

141k

142k

164k

Capital Expenditure

-70k

-18k

-105k

-370k

Net PPE

768k

1.24M

1.93M

625k

Intangible and Goodwill Schedule

Year

2021

2020

2019

2018

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep